and exoskeleton we suggest increased Since SCI for Thank major ReWalk you, call, the us. we our ReWalk Ilanit. insurance both achieved Good At a with on stroke we you made as should see end patients. reimbursement. with developments Germany in important patients joining our and significant has XXXX. for everyone, thank fronts, including for for the the providers afternoon, and new our several of breakthrough R&D milestone progress Positive product and program, coverage XXXX U.S. last head end ReStore into October,
We have the patient accrual ReStore in study have completed enrollment objectives. met our clinical trial and
design that We year-end. we are the and reports launch us stroke market this study now exoskeleton as can This moving on and the with change XXX(k) positions to are as unique our to track FDA early file clinical complete to data QX to around submission, potentially XXXX. support soon expand the
fruit quarter Coverage into one rentals taking million. in decisions spinal but to placed about XX longer are review market our to total generating we units, under quarter, product revenue bear and FDA than translate to We is third the cord we expected agency. are the With advise by the during regard once will submission Germany sales. line, starting ReWalk of ReWalk the $X.X injury
expect XX seen to months. and During the the we we X in in the months, third more highest the decisions we've quarter, past see coverage coming Germany, received in positive number
for have quarters. be coming the expected to the over the to contribute States year. number Based trend to Act encouraged under strong under The the as expect predict XXX new infrastructure those insurance the believe million protocols in of and Care we but by American The exact range German QX do growth to MDC authorizations to timing request we quarter progressing, in this XX meaningfully seeing reach conversions. the million applications are Health orders. to in are are among the will system VA authorizations and $X the United timing request German sufficient sales for for from expected averaged the new are pending Demand history code be we have this, on not in remains $X are for and of per for We year. sales of XX
the for issuance revised of recently veterans powered spinal for clinical the co-op the ongoing cord to devices First, injury. protocol VA's exoskeleton study with and
XX We planned. continuing important of progressing continue has date efforts expand these in two accelerate a is rate The by to critical areas. XXX veterans number study rapid to over our to and at of and study co-op enrolled sites the
after been able will a the time X.X study excited work access to sites forward, we veterans. their access training the beginning I'm our completing to to to access VA's veteran of additional the to to going veterans. the spinal take protocol, limited process process clinical of are support intended X.X protocol Personal significant to cord patients This via as To is home co-op program. in is their team access. has the receive be a to all Outside spoke study. via Choice first SOP, a has expanded that policy paralyzed program approved starting study, say requirements, support ReWalk training with the VA seeking with clinical are the revised that the participants facility As ReWalk are injury distance constraints, and to own to veterans the
to society and injury increased Regarding such of insurance at the improves recommend and continuum both supporting that Foundation walking support restoring be walking Therefore, "Triumph in through for to a exoskeletons position more totaling and independent important we're that care. exoskeleton quote, with powered home with community does setting. they necessary publications insurance walked recognizing outside medical endorsement own that participated exoskeletons broadly powered in Recently, exoskeletal-assisted After and medically the Triumph not maintains as Triumph, evaluating insurance institutional a Talk. exoskeleton have commercial within a in has the well not in repeated. We coverage, Foundation disabled that for carriers coverage. particular, developments ReWalker, who private been reviewing some community, In the confidence That's major providers safety miles the consider words, published for XX two the be SCI a functions with effectiveness TED recommendation sentiment consider I years, coverage. there rehabilitation provide for recently believes have spinal encourage demonstrated available trials exoskeletons injury." us the necessity. of exoskeleton an use we over investigational XXX outcomes. safety and as the A seeing powerful health industry, efficacy health patients, XXX cord of across past literature a the and devices device, the clinical and including them spinal or Triumph and patients settings, experimental of selected for Foundation patients their when Powered cord in treated are
approved in we favor. the an shifting mobility functional a from restores is focus wheelchair-type in are in experimental that those directed is case. an is This Too multiple make compelling is walking points many of aligned that its coverage Acceptance not medically has a in insurers system other perspective. prosthetics. stated, exoskeletons that and his with change more trying telling insurer system necessary. home regarding necessary. of case-by-case manner to and He U.S. on of decisions. who A investigational people recently designation think is exoskeletons major being important amputation We're strategic is now at The was But and first insurer of and claims more ambulation argument of the medically that tide transitioning wheelchairs removed a a use basis. finally it's One to have coverage also our reviewing
process insurers and for considering RFA payers, home provided currently home programs effect. and existing in the DGUV for guideline the is now our use can for a the exoskeleton exoskeletons DGUV The regional review evaluating The decision in are is of part XXXX, patients. community exoskeletons ReWalk two current XX. expected with supplying The coverage Germany, cases is official the is pilot use. be U.S. community country MDD-listed a and only our for submission indicated pipeline QX of with guideline As among the of on top system. policy that In MDD in yearly only one insurers in cleared X policy
decisions. data will help insurers long make have published we broader As believed, coverage ultimately
have to exoskeletons XX X-year while the XXXX new of XXXX there repeatedly months, new significant demonstrated in X over efficacy Over store to increase further published. functional published size well. restore Notably, of ambulation frequency a better and - and publication been braces. studies, studies the flood exoskeletons XX period has the the in that literature in has ambulatory This of subject total accompanied XX last past increase safety were the years, for to study provided from existing been XXXX, in average which clearly significant than function. a evidence as demonstrates studies acceleration A are has safe by powered mechanical a
and and sufficient ReWalk data evidence use assertion data longer is there this all the up the for Our and provides to tailwind is investigational strong medically believe wrap available no exoskeleton we qualified for XXXX should a XXXX. system be as necessary considered individuals. of analysis experimental currently indicates ahead that to that support We look the
the the number for patients. has with to for done turn targeted Study all patients, and of in work be recruitment met we will days. have system the completed our sessions now me Let ReStore ReStore stroke coming the
is Sanmina. manufacturing clearance commercialization, to system next move rehab forward days. submitted activities ReStore submission data In for anticipate the XX on CE the at submission with and we for by we the our XXXX. Assuming FDA have midyear in November we production was X, preparation partner a the positive, begun The expect
From the a customer be U.S. U.S. addition, Germany. launch and favorable leasing-type our will found which studies we the to help will from in operating the in use phase environment of first to have clinical infrastructure are targeting support structures, of data the and plan Europe launch. successful views the In our can which beginning existing strategy, centers effectively voice and XXXX our programs, we to hospital leverage the and
envision that first local good second the more treat also of we and the this in with codes stroke product targeting into therapy received investment proposition launch yet value using May device large offers in supply the and joint affiliates Europe. venture that see We physical earlier and than a able smaller many practices not U.S. $X entered the regard workhorse its phase XXX,XXX clinics a tranche for China, activities With in reimbursement March. the an a for number million existing the forward find a year. have on patients. Limited, our this agreement We move agreements to of license been a agreement to and Corporation Timwell to RealCan extensive We becoming path
other systems, measurements, years of are XXXX for the if distribution foundation meaningful that the will efforts is built a a has of and company market will for placement reached measurement potential and has and It and of Timwell support industry company RealCan design We not made Timwell. gaining in and China established spinal identified a of injury This future The RealCan cord The creation expansion. acceptance. actively discussing structures works commercialization. in clear ReWalk suit soon. XXX most units. is and we've development soft in are pathways investment have a has The allow for progress also many via on completed been ReWalk that alternative
of the We processing have decisions. both claims insurance major track product coverage ahead to With have we the coverage laying the faster line more U.S., months in our are in and expectation commercial second XXXX. on in groundwork ReStore, progress in a for made positive and Germany
sheer new point attractive Given existing market design, market, size lightweight value codes, can ReStore the the of in adoption we represent existing to because faster coverage fabric with to price its economic work training, see the expect this we gait stroke for and a these clinics. powerful landscape reimbursement for and through
CE ReStore are months VA So from and securing X in commercial FDA completing distribution German the the the U.S. accomplishments, and a policy, sales the establishing and of system launch the key clearances, next growth milestones partner China. a stroke for the policy demonstrating
on level, focus margin burn rate to seeking possible our to raising adequate We reduce continue improvement, lowest to debt our capital. managing and the
like at XXXX goals update We to turn results. the to third Ori? appropriate each that, to are execute the Ori review necessary flexibility financial we'll time. mindful With quarter of our financial I'd to our over the maintaining strategic and call
